Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | ELVN-002 |
Trade Name | |
Synonyms | ELVN002|ELVN 002 |
Drug Descriptions |
ELVN-002 selectively inhibits ERBB2 (HER2), including mutant ERBB2 (HER2), potentially leading to decreased tumor cell proliferation and reduced growth of ERBB2 (HER2)-expressing and ERBB2 (HER2)-mutant tumors (Cancer Res (2023) 83 (7_Supplement): 4019). |
DrugClasses | HER2 Inhibitor 40 |
CAS Registry Number | NA |
NCIT ID | C192219 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ado-trastuzumab emtansine + ELVN-002 | Ado-trastuzumab emtansine ELVN-002 | 0 | 1 |
ELVN-002 | ELVN-002 | 0 | 1 |
ELVN-002 + Trastuzumab deruxtecan | ELVN-002 Trastuzumab deruxtecan | 0 | 1 |